Ethical Pharmaceutical

What Ethical Pharmaceutical does

Ethical Pharmaceutical is a Dominican Republic-based pharmaceutical manufacturer founded in 1972 by Luis Andrés Lebrón Tejera, headquartered at Prolongación Avenida 27 de Febrero No. 1501 in Santo Domingo. The company produces and commercializes medications for human consumption across three dosage form categories — liquids (soaps, solutions), semisolids (ointments), and solid-dose tablets — and operates a vademecum of 325 products spanning ethical (prescription), generic, and popular (over-the-counter) medications across therapeutic areas including cardiovascular, anti-inflammatory, antibiotic, respiratory, gastrointestinal, contraceptive, and vitamin supplements. Its modern pharmaceutical plant, inaugurated in 1999, is described by the company as a model facility for the Caribbean/Latin American region. Manufacturing is supported by ISO 9001, ISO 14001, and Good Manufacturing Practices (BPM) certifications, and the company has developed proprietary branded formulations in-house since acquiring technology transfer from European suppliers in the 1980s.

The company generates revenue exclusively through pharmaceutical product sales, distributed through a pharmacy network and direct supply to healthcare facilities across the Dominican Republic. Its go-to-market is sales-led, targeting both healthcare professionals (via a dedicated 'Profesionales de la Salud' section and medical education resources) and the general patient population (via prescription and OTC pharmacy channels). Pricing is not publicly disclosed; the mission statement explicitly targets 'produce quality medications at low cost.' The company is privately held with no disclosed parent, subsidiaries, funding rounds, or M&A activity, and operates within a single-country geographic footprint. The founder-founded ownership structure and absence of institutional investment suggest a closely-held, family-influenced business.

Customer base is horizontally segmented across therapeutic categories with no disclosed named enterprise customers or anchor accounts, implying a fragmented, distributed end-buyer base. Digital presence includes a corporate website with vademecum catalog, plus Instagram, LinkedIn, and Facebook channels, representing limited but present digital engagement with healthcare professionals and consumers. The company's stated vision is to 'continue being leaders in the national pharmaceutical market and venture into other markets,' signaling aspirational geographic expansion beyond the Dominican Republic.

Name

Ethical Pharmaceutical

Legal name

Ethical Pharmaceutical

Website

https://ethical.com.do

Company type

Private

Founded year

1972

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Ethical Pharmaceutical is a privately held Dominican Republic pharmaceutical manufacturer founded in 1972, producing 325 ethical, generic, and OTC medications across liquids, semisolids, and solid dosage forms. It distributes through domestic pharmacy and healthcare facility channels and self-reports as the Dominican market leader.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Pharmaceutical manufacturing
• Generic medications
• Prescription drugs
• OTC medicines
• Pharmaceutical products

Headquarters

HQ city

Santo Domingo

HQ country

Dominican Republic

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: The company generates revenue through the production and sale of pharmaceutical medications for human consumption, including ethical (prescription), generic, and popular (OTC) drug categories. Products span multiple therapeutic areas including cardiovascular, anti-inflammatory, antibiotic, respiratory, and vitamin supplements.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Ethical Pharmaceutical manufactures and sells a portfolio of 325 pharmaceutical products for human consumption in the Dominican Republic, spanning ethical (prescription), generic, and popular (over-the-counter) medications. The company produces in multiple dosage forms—liquids (soaps, solutions), semisolids (ointments), and solids (tablets)—including proprietary branded products such as Dermofull, Fisiolax, Hipermex, Nitrenol, and Urofull, developed in-house at their ISO-certified plant in Santo Domingo.

Product overview

Ethical Pharmaceutical is a Dominican Republic-based pharmaceutical company founded in 1972 that produces and commercializes medications for human consumption. The company operates a comprehensive product portfolio of 325 pharmaceutical products categorized as ethical (prescription), generic, and popular (over-the-counter) medications. The product portfolio includes cardiovascular medications (Akavar line of Candesartán-based antihypertensives, Amlodipina Ethical, Metoprolol Ethical, Ara II-D), respiratory products (Monteluk-L, Adek Mucolítico, Adek Forte), gastrointestinal products (Doloprazol), contraceptives (Aliad), and general health products (Abarcal). The company manufactures in multiple pharmaceutical forms including liquids, semi-solids (ointments), and solid-dose tablets, and has developed proprietary brand products including Dermofull, Fisiolax, Hipermex, Nitrenol, and Urofull alongside generic formulations. Ethical Pharmaceutical's new pharmaceutical plant opened in 1999 serves as a model facility for the Caribbean region.

Differentiator

Problem solved

Functional benefit

Products and services

• Vademécum (Product Catalog)
• Doloprazol Analgesic-Anti-inflammatory-Gastroprotector combination product containing Esomeprazol 500 mg and Naproxeno 20 mg, presented as 20 enteric-coated tablets for oral administration.
• Monteluk-L Anti-asthmatic combination product containing Montelukast 10 mg and Levocetirizina 5 mg, presented as 30 tablets for oral administration.
• Ara II-D Anti-hypertensive combination product containing Losartán 100 mg and Hidroclorotiazida 25 mg, presented as 30 tablets for oral administration.
• Metoprolol Ethical Anti-hypertensive beta-blocker product containing Metoprolol 50 mg, presented as 100 tablets for oral administration.
• Amlodipina Ethical Anti-hypertensive calcium channel blocker containing Amlodipina 5 mg, presented as 30 tablets for oral administration.
• Akavar (Candesartán line) Anti-hypertensive angiotensin II receptor blocker product line containing Candesartán in 8 mg, 16 mg, and 32 mg dosages, available as 30 tablets. Also offered in combination products (Akavar-A, Akavar-D, Akavar-3) with Amlodipina and/or Hidroclorotiazida.
• Aliad Contraceptive product containing Ciproterona 2 mg and Etinilestradiol 0.035 mg, presented as 21 tablets for oral administration.
• Adek Mucolítico Mucoregulator-Expectorant-Anti-inflammatory product containing Lisozima 50 mg and Carboximetilcisteína 500 mg per 10 mL, presented as 100 mL oral solution.
• Adek Forte Bronchial epithelium protector and regenerator containing Lisozima, Vitaminas A, C, D3, and E, presented as 100 mL oral solution.

Quantifiable outcome

• Leader in national pharmaceutical market ranking including international laboratories

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered regulatory and supporting.

• Oficina Nacional de la Propiedad Industrial (ONAPI)regulatoryOthersGovernmental regulatory body for intellectual property in the Dominican Republic. Ethical Pharmaceutical works with ONAPI for regulatory and intellectual property matters related to their pharmaceutical products.
• Ministerio de Salud PúblicaregulatoryOthersMinistry of Public Health - the governmental health authority in the Dominican Republic. Ethical Pharmaceutical collaborates with this ministry for regulatory compliance and pharmaceutical product approvals.
• Ministerio de TrabajosupportingOthersMinistry of Labor - governmental body overseeing employment regulations. Ethical Pharmaceutical maintains compliance with labor regulations as part of their corporate policies.
• Ministerio de Medio Ambiente y Recursos NaturalessupportingOthersMinistry of Environment and Natural Resources. Ethical Pharmaceutical works with this ministry as part of their environmental policies and sustainability management system.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/lab.ethicalpharmaceutical
• LinkedInlinkedin.com/company/ethical-pharmaceutical
• Instagraminstagram.com/ethicalpharmaceutical/?igshid=nb6om7xvk320

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ethical Pharmaceutical